Allison Transmission enters the final stretch of Q3 with a clean divergence at its core: the stock is up 7% over the past month and short sellers are backing away, yet the CEO sold nearly $3.6 million worth of shares at the peak — a detail worth unpacking before October's earnings.
The short side of the trade has become increasingly thin. Short interest has dropped 22% over the past 30 days to just 3.8% of the free float, down from around 5% in late July. Borrow is essentially free at 0.56% cost-to-borrow, and availability is running at over 2,000% — meaning there are roughly 20 shares available to lend for every one already borrowed. That is an exceptionally loose borrow market. The ORTEX short score has eased to 37 from a brief spike to 46 on August 21, confirming the retreat rather than flagging renewed bearish conviction. Options traders are not adding much pressure either: the put/call ratio at 0.40 is marginally above its 20-day average of 0.36, well within normal range and nowhere near the 52-week defensive peak of 1.57. Positioning, in aggregate, looks relaxed.
The insider angle is harder to wave away. CEO David Graziosi sold 26,708 shares through option exercises on August 21, then sold 26,708 open-market shares across three tranches at prices ranging from $132 to $134 — netting roughly $3.55 million in total proceeds. None of those sales were flagged as executed under a pre-arranged 10b5-1 plan, which makes them discretionary rather than scheduled. The timing — right at the stock's recent high and immediately after a 7% one-day earnings pop — means the transaction reads as selling into strength rather than routine portfolio management. CLO Eric Scroggins also sold 1,050 shares on August 11. Net insider activity over the past 90 days totals a negative $4.2 million across roughly 31,700 shares.
The Street is cautiously constructive but not enthusiastic. Analyst moves from mid-July are the most recent on record, and they tell a mixed story. JP Morgan lifted its target to $145 while staying Neutral; Morgan Stanley nudged its Equal-Weight target up to $130; Citi cut its target to $125 from $135, also staying Neutral. The consensus mean target of $139 sits about 6% above the current price of $131, which implies limited upside in the eyes of a market that is broadly sitting on Hold. One factor score stands out: the analyst recommendation differential ranks in the 94th percentile, suggesting that relative to the broader universe, the analyst community is leaning positive on ALSN even if the absolute ratings remain neutral. Forward EPS growth ranks in the 69th percentile on a 12-month basis. The valuation is not stretched — PE near 12x and EV/EBITDA around 7.5x are modest multiples for a business with Allison's margins — but neither is the stock cheap enough to attract fresh upgrades.
Among peers, ALSN has diverged sharply. WAB fell 3.2% on the week and NDSN dropped nearly 2%, while Allison gained 3.9%. AGCO was the week's outlier with a 17.6% surge, but that move appears idiosyncratic. The broader industrial peer group is tracking softer, which makes Allison's hold-and-grind-higher pattern more notable — and also gives the CEO's decision to sell at current levels more context.
The earnings history adds one more data point worth holding in mind. The most recent print on August 3 produced a 7% next-day gain and nearly 9% over five days — the kind of move that explains both the recent short squeeze and the CEO's decision to lock in gains. Q3 results are pencilled for October 28. Between now and then, the key variable to watch is whether the Street's target consensus begins to move above $139 or whether more neutral-rating target cuts — like Citi's — signal that the post-earnings re-rating has largely run its course.
See the live data behind this article on ORTEX.
Open ALSN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
